Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.

NCT02446041 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02446041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2015
Enrollment
10,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive, pulmonary disease